2020 ANNUAL BIOTECHNOLOGY CONFERENCE

UNDERSTANDING THE IMPACT OF THE PANDEMIC ON ENTREPRENEURSHIP AND BIOTECH STARTUPS

THURSDAY, NOVEMBER 5, 2020
3:00 - 5:30PM EST

TO REGISTER, VISIT WWW.PABCEEVENTS.ORG
3:00 – Welcome and Introductions - Timothy M. Block, Ph.D., and Louis P. Kassa, M.P.A

3:15 – Remarks from Senator Steve Santarsiero

3:17 – Welcome MC, Grant Castor


4:04 – Presentation 3 – Michele Cleary, Ph.D., The Mark Foundation for Cancer Research

4:25 – Break

4:30 – Welcome back and trivia

4:34 – Presentation 4 – Wendy Yeh, M.D., Vir Biotechnology

4:55 – Presentation 5 – John Maraganore, Ph.D., Alnylam Pharmaceuticals

5:15 – Thank you to our sponsors and closing remarks - Timothy M. Block, Ph.D., and Louis P. Kassa, M.P.A
Building community together

COMMITTED TO LOCAL
About the Annual Biotechnology Conference

Welcome to the Annual Biotechnology Conference, hosted each year by the Pennsylvania Biotechnology Center (PABC) to spark conversation on a topic of interest for the life sciences community and to provide a networking opportunity for biotech businesses in our region.

The event is co-sponsored by the PABC and the Baruch S. Blumberg Institute, which manages the PABC. Held in past years at the PABC, the 2020 Biotech Conference will be online, yet interactive. We expect it will attract a larger-than-ever audience from around the country and overseas, based on the success of the PABC's online Entrepreneur Spotlight in July.

This year’s theme is “Understanding the Impact of the Pandemic on Entrepreneurship and Biotech Startups,” and will focus on the challenges and the opportunities presented by COVID-19 for life science startups.

The PABC is proud of our contribution to the growth of the biotechnology industry in our region. Our ecosystem is unique, having components that include nonprofit partners, academics, sophisticated shared resources and community collaboration. The results speak for themselves: Entrepreneurs at PABC have created more than $2 billion in value and launched several publicly traded companies. R&D at the facility has produced two new FDA-approved drugs and two new medical devices that are now on the market, with more than 10 new drugs and medical devices in clinical trials.

The PABC recently established its own venture fund to provide early stage funding to new businesses within our center. Our website provides details about PABC membership options and upcoming events.

We hope that today’s conference helps life sciences entrepreneurs as they seek funding to grow their business. We appreciate your support.
THE HEPATITIS B FOUNDATION, BARUCH S. BLUMBERG INSTITUTE & PENNSYLVANIA BIOTECHNOLOGY CENTER

Congratulate

Louis P. Kassa, MPA

Industry Era Magazine - 10 Best COOs of 2020
The nonprofit Pennsylvania Biotechnology Center (PABC) is one of the nation’s most successful life sciences incubators, offering state-of-the-art laboratory and office space to early stage biotech companies, as well as the Hepatitis B Foundation and Blumberg Institute.

The center uses a highly successful services-based approach to nurture and guide its member companies to success, advancing biotechnology, maximizing synergies among nonprofit scientists and their commercial colleagues, and launching new ideas and discoveries that will make a difference. PABC is in Bucks County, in the heart of the Philadelphia-New Jersey pharma belt.

Located on Old Easton Road next to the Doylestown Airport in Buckingham Township, the PABC opened its doors in 2006. The center has more than 70 member companies, 41 of which have operations in the facility. PABC-member companies currently employ about 300 highly skilled scientists, staff and students.

We began construction on a major expansion of our facilities this summer. The price tag is $19 million, including land acquisition. The project includes a new 37,000 square-foot rectangular, two-story building between two existing structures, which will mean a 40% expansion of the PABC. It will provide 15,000 square feet of new laboratory space and a larger main entrance plus more offices, conference rooms and a 200-seat event space. The expansion will lead to additional jobs at the facility, perhaps more than 100, plus dozens of new companies and millions of dollars in commercial activity. It will be completed by October 2021.
Setting science in motion to create a better world

From breakthrough discovery to agile delivery, we offer an extensive portfolio of mission-critical products, services, and solutions. We are a trusted global partner to customers in the life sciences, advanced technologies, and applied materials industries.

VWR, part of Avantor, provides an integrated, seamless purchasing experience optimized for your success.

Learn how the new Avantor is moving forward at avantorsciences.com

@2020 Avantor®, Inc. All rights reserved.

About Antengene

Antengene is a biopharmaceutical company with integrated drug discovery, clinical development, manufacturing and commercialization anchored in Asia Pacific region with global layout, aiming to provide the most advanced and first-in-class anti-cancer drugs and other treatments for patients in China, the rest of Asia and around the world. In April 2017, Antengene (now officially acquired by BristolMyers Squibb), a global leading innovative biopharmaceutical company became a founding partner and obtained an equity position as an investor in Antengene. Antengene has obtained 7 IND approvals with 6 first-in-class drugs in more than 10 ongoing cross-regional clinical trials in Asia Pacific region, and has build a product pipeline of 12 clinical and pre-clinical stage programs. The vision of Antengene, “Treating Patients Beyond Borders.” is to meet the unmet medical needs of patients in Asia Pacific region and around the world through research & development and commercialization of first-in-class drugs. For more information, please visit www.antengene.com

For your reference:

Glycotest

A New Paradigm for Early Diagnosis and Surveillance For Liver Cancer

Lawrence Cohen, CEO
Larry.Cohen@Glycotest.com
www.glycotest.com
The Baruch S. Blumberg Institute is an independent nonprofit research institute, established in 2003 by the Hepatitis B Foundation to advance its research mission.

Today, it is one of the nation’s leading centers for translational research, particularly for hepatitis B and liver cancer. The Institute supports drug discovery, biomarker discovery and translational biotechnology around common research themes such as chronic hepatitis, liver disease, and liver cancer in an environment conducive to interaction, collaboration and focus.

The Blumberg Institute’s mission is to use discovery science to find new therapies and biomarkers for hepatitis B and liver cancer; to advance its research discoveries through traditional scholarship and educational opportunities; to nurture biotechnology; and to promote public health outreach programs to improve the quality of life for those affected by chronic hepatitis B worldwide.

The Institute is named for Dr. Baruch Blumberg, who won the Nobel Prize in 1976 for discovering the hepatitis B virus.
The Pennsylvania Biotechnology Center (PABC) community has numerous companies engaged in research and development associated with COVID-19. Additionally, scientists with the nonprofit Baruch S. Blumberg Institute, which manages the PABC, are working on several projects that show promise for preventing and treating COVID-19.

Timothy M. Block, Ph.D., president of both the institute and PABC, says Blumberg scientists are conducting research with a drug candidate they developed years ago to determine if it could be an effective treatment for COVID-19. "We have been working on antiviral drugs for two decades at Blumberg," Dr. Block said. "Our focus has been hepatitis B, liver cancer and other cancers, but some of the drugs we have discovered appear to have activity against other viruses."

Dr. Block and other scientists at the PABC received four state grants in August for pandemic-related work, including a $430,000 grant to build new labs, offices and instructional space to accommodate COVID-19 R&D. There’s more on the PABC website.

For more information on the Blumberg Institute’s COVID-19 research efforts, visit https://www.blumberginstitute.org/COVID19research.
Life Sciences-Minded Full-Service Legal Advice.

Why Wilson Sonsini?
- Wilson Sonsini guides promising life science, technology, and growth enterprises worldwide through their business life cycle, from incorporation to exit.
- Our services include corporate law and governance, public and private financings, mergers and acquisitions, litigation, commercial and technology transactions, and intellectual property counseling, among other areas.
- More than 100 Wilson Sonsini patent professionals hold a Ph.D. in a field of life science or engineering important to growth-stage companies.
- Our FDA regulatory, business advisory, and university spinout practices are integrated into a company’s IP and corporate needs.

Market Recognition
- Named “Venture Capital Firm of the Year” at the 2019 LMG Life Sciences Awards
- Ranked as #1 Life Sciences Law Firm for 2017 and 2016 (Life Sciences Law Firm Index by Lake Whillons)

Craig Kenesky, Ph.D.
Patents and Innovations
North Atlantic Leader
ckenesky@wsgr.com
212-497-7767

Medix
Positively Impacting Lives

Medix is here to help you find the right scientific talent to fit your highly-skilled team. Our hiring experts support clients with staffing, workforce solutions and consulting.

- Pharmaceutical
- Biotechnology
- Medical Device
- Clinical Research Sites
- Food and Beverage

Reach out to your local Medix representative Veronica Onesi, to learn more:

vonesi@medixteam.com
215-201-2014

https://www.wwmponline.com/
Nadia Lovell
U.S. Equity Strategist
J.P. Morgan Global Wealth Management

Nadia is a U.S. Equity Strategist for J.P. Morgan Global Wealth Management. As part of the Global Equity team, Nadia helps develop the Private Bank’s U.S. equity views and identifies and markets stock-specific and thematic investment opportunities across U.S. equities. Before joining the Private Bank in 2014, Nadia spent 5 years in J.P. Morgan Equity Research, as a member of the Institutional Investor magazine ranked Media equity research team, where she published research and provided investment advice on over 20 companies. Prior to that, she was an investment product specialist, primarily focused on fixed-income mutual funds, at American Funds of The Capital Group Companies.

Nadia received a B.A. in Math and Physics from Smith College and an M.B.A. from NYU Stern School of Business. She is a Board member of Hunts Point Alliance for Children.
Eric Freedgood, CPA, CFA
Executive Vice President, Chief Innovation Officer, Senior Portfolio Manager
Pinnacle Associates, LTD

Eric began his professional career in 2003 after graduating with honors from Binghamton University. Upon graduating, he joined Ernst and Young (EY) where he audited and valued complex derivative instruments for large financial institutions, banks and funds. It was during this time he obtained his CPA license which he still holds today. After his time at EY he joined Pinnacle Associates, Ltd- a Registered Investment Advisor in 2006 as an associate portfolio manager. In 2009 Eric obtained his Chartered Financial Analyst designation which he currently maintains. Over the years at Pinnacle, Eric has introduced many new portfolio strategies to clients that address current market and client needs and circumstances. Eric has focused his efforts on helping high net worth clients as well as small and medium sized institutions achieve their growth, income and risk-defined goals. Eric has always focused his clients’ success on what he refers to as the “two “C’s” of customization and communication. In 2011, Eric was asked to be a partner in the firm, which he gladly accepted. In 2020, given many of the new initiatives brought to Pinnacle over the years, Eric was asked to serve as the firm’s Chief Innovation Officer- a new roll he is very excited about to ensure discovery and implementation of new strategies, tools and ideas in the investment program. Eric is an avid reader, runner, and hiker and he recently has taken up gravel biking. His main joy, however is spending time with his wife Rachael and their two young sons.
Michele Cleary, Ph.D
Chief Executive Officer
The Mark Foundation for Cancer Research

Michele Cleary joined The Mark Foundation for Cancer Research as Chief Executive Officer in January 2017. Since that time, she has recruited a high performance scientific and administrative team and built a global research portfolio of over $100 million in grants and early-stage investments. Prior to her role at The Mark Foundation, Michele was Vice President at Bristol-Myers Squibb (BMS). At BMS, she led early clinical and translational research teams using cutting-edgetechnologies to accelerate drug discovery and development for cancer and other diseases. Before joining BMS, Michele held several senior level positions at Merck & Co., Inc. overseeing the development and application of innovative platforms aimed at understanding molecular mechanisms of cancer, identifying new therapeutic approaches for multiple diseases, and functionally validating novel drug targets identified through human genetics. At Merck, her research teams also conducted pioneering work using genetic screens for new drug targets and biomarkers in cancer.

Michele is co-author of more than 50 primary research papers and co-inventor on multiple patents for new technologies with direct application to drug development. She received a PhD in Molecular Microbiology and Genetics from Stony Brook University and completed graduate research at Cold Spring Harbor Laboratory followed by postdoctoral training at Princeton University.
Wendy Yeh, MD  
Senior Vice President, Clinical Research  
Vir Biotechnology

Dr. Yeh has served as the Senior Vice President of Clinical Research at Vir since August 2020. Prior to that, she was at Principia Biopharma in South San Francisco leading the clinical development of BTK inhibitors in multiple immune-mediated diseases. From 2012-2019, Dr. Yeh was at Merck Research Laboratories in Boston where she made significant contributions to the Merck Infectious Disease portfolio, such as the development of multiple hepatitis C virus compounds including the approval of a HCV combination, as well as the life cycle management of the CMV antiviral program.

After receiving her undergraduate degree in Biological Sciences from Stanford University, Dr. Yeh earned her M.D. from University of Washington in 2000 and completed her Internal Medicine training at the Brigham and Women's Hospital and her Infectious Disease fellowship at Massachusetts General Hospital/Brigham and Women’s Hospital in Boston. Prior to joining industry, Wendy previously held the position of Assistant Professor in Medicine at Harvard Medical School.
Since 2002, Dr. John Maraganore has served as the CEO and a Director of Alnylam. Prior to Alnylam, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. As Senior Vice President, Strategic Product Development for Millennium, he was responsible for the company’s product franchises in oncology, and cardiovascular, inflammatory, and metabolic diseases. He was previously Vice President, Strategic Planning and M&A and, prior to that, he was General Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium. Before Millennium he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. At Biogen, Dr. Maraganore invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection, formerly HIRULOGTM and currently marketed by The Medicines Company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., and the Upjohn Company.

Dr. Maraganore received his Master of Science and Ph.D. in biochemistry and molecular biology at the University of Chicago. He is a member of the Board for Agios Pharmaceuticals and Biotechnology Industry Organization (BIO) Board and is a member of the BIO Executive Committee.
We thank our sponsors for supporting the 2020 Annual Biotechnology Conference and for helping the Pennsylvania Biotechnology Center and the Baruch S. Blumberg Institute to nurture the growth of biotechnology companies in the region.

Diamond Sponsor

UNIVEST
BANKING | INSURANCE | INVESTMENTS

Emerald Sponsors

Alcamí
Vir Biotechnology
VWR International/Avantor
West Pharmaceuticals
Wilson, Sonsini, Goodrich & Rosati
Zero to 5ive
We thank our sponsors for supporting the 2020 Annual Biotechnology Conference and for helping the Pennsylvania Biotechnology Center and the Baruch S. Blumberg Institute to nurture the growth of biotechnology companies in the region.

Ruby Sponsors

Clifton, Larson, Allen LLP
EisnerAmper
Fox Rothschild LLP
WorldWide Life Sciences

Sapphire Sponsors

Antengene
Fox Chase Chemical Diversity Center
Gilmore & Associates
Glycotest, Inc
J.P. Morgan
SEEDING TOMORROW’S DISCOVERIES TODAY

Hatch BioFund, LP is an early-stage life sciences venture fund formed as a companion fund to the Pennsylvania Biotechnology Center (PABC), one of the most successful life science incubators in the country.

With a target fund size of $50M, Hatch plans to implement a two-pronged strategy of providing seed stage funding and space in its BioAccelerator to researchers from academia, hospitals and large pharma, and Series A funding to those promising companies from within the BioAccelerator, the PABC Incubator, and other opportunities sourced through its extensive network.

AN ECOSYSTEM OF VALUE CREATION

<table>
<thead>
<tr>
<th>Pennsylvania Biotech Center (PABC)</th>
<th>Hatch BioAccelerator</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Home to Hep B Foundation, Blumberg Institute, PABC Incubator and Hatch BioAccelerator (coming 2020)</td>
<td>• New BioAccelerator being built; completion date of 2020</td>
</tr>
<tr>
<td>• Ecosystem of science and collaboration</td>
<td>• Funding companies from concept stage</td>
</tr>
<tr>
<td>• Abundant scientific and management talent</td>
<td>• Hatch BioAccelerator Program will combine space, money, business creation, and advisory services</td>
</tr>
<tr>
<td></td>
<td>• Best science receives follow-on funding</td>
</tr>
</tbody>
</table>

$50M Early-Stage Life Sciences Fund

<table>
<thead>
<tr>
<th>PABC Incubator</th>
<th>Experienced Team</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Rated among top incubators in the U.S.</td>
<td>• Experienced Management</td>
</tr>
<tr>
<td>• Home to 45 companies</td>
<td>• High profile Scientific Advisors</td>
</tr>
<tr>
<td>• Synergetic and collaborative environment</td>
<td>• Seasoned Biotech investors</td>
</tr>
<tr>
<td>• Drug development and business services support</td>
<td></td>
</tr>
</tbody>
</table>

CONTACT US

Vladimir Walko, MS, MBA  vwalko@hatchbiofund.com  610-716-1776.

Pennsylvania Biotechnology Center, 3805 Old Easton Road, Doylestown, PA 18902  215-589-6300
BECOME A MEMBER OF THE PENNSYLVANIA BIOTECHNOLOGY CENTER

Regional and national memberships available

Access one of the most successful life sciences incubators in the country.

The Pennsylvania Biotechnology Center (PABC) is now extending annual memberships regionally and nationally. Located in the middle of the pharma belt between North Jersey and Philadelphia, the PABC was named one of the most successful biotechnology incubators in the country, according to a 2018 International Business Innovation Association survey. This is a unique opportunity to become a member of our scientific and entrepreneurial community.

Benefits for members include:

- Access to a dynamic and growing community of life sciences companies, their scientists and business experts, researchers with the Blumberg Institute and a network of finance and business development leaders in the region.

- Invitations to participate in events and activities conducted every month at PABC: our Entrepreneur Spotlight, Vendor Expos, Regional Biotechnology Conference and Lunch-and-Learn sessions.

- Quarterly newsletter featuring company bios and news from the center (scientific breakthroughs, advances, etc.)

- World class seminars, such as a recent one with Scott L. Friedman, M.D., Dean for Therapeutic Discovery at the Icahn School of Medicine in N.Y.C.

- Regional updates and information from the heart of Cellicon Valley!

- Use of our conference rooms, office space, mail room and other facilities, which are being expanded to add an auditorium, lab space and new offices.

www.pabiotechbc.org

For more, please contact Loretta Molle, 215-489-4902 or loretta.molle@bblumberg.org
SUPPORT AT EVERY STAGE

Comprehensive solutions for your early phase drug product development and scalable manufacturing processes that support clinical to commercial supply.

DEVELOPMENT  STERILE FILL-FINISH  ORAL SOLID DOSE  TESTING

alcami:  alcaminow.com

MAKE YOUR MARKETING COUNT!

LOGOS  WEBSITES  PUBLIC RELATIONS  INVESTOR MATERIALS

ZERO TO 5IVE

MICHELLE@OTO5.COM  OTOS.COM
Whether your company is in development or already in the market, we can help guide you to and through what’s next.

Proud to support the Hepatitis B Foundation

Dan Hayes | 484-533-6220
CLAconnect.com/lifescience

ADVISORY | OUTSOURCING
AUDIT, TAX, AND CONSULTING
©2020 CliftonLarsonAllen LLP

Life Sciences and Biotech companies rely on Fox for guidance in:

- Intellectual Property
- Licensing
- Private Equity
- Regulatory and Compliance
- Tech Transfer
- Venture Capital

Fox Rothschild LLP
ATTORNEYS AT LAW
950 attorneys nationwide

Elizabeth D. Sigety
215.918.3554

Loren David Danzis
215.918.3561

foxrothschild.com
From startup to exit.
It’s time for a financial partner
who understands you.

At J.P. Morgan Private Bank, in Philadelphia, across the Mid-Atlantic and globally, we work
to understand your personal definition of success. We help you define and realize your
unique goals for today, tomorrow and across your lifetime. So you can make the impact
you want to have on your life, family, business, community, and even the world.

Let’s connect.

privatebank.jpmorgan.com/philadelphia

Chris Cortina
Vice President
215.640.3539
christopher.s.cortina@jpmorgan.com

J.P. Morgan

*J.P. Morgan Private Bank™ is a brand name for private banking business conducted by JPMorgan Chase & Co. and its subsidiaries worldwide.

INVESTMENT PRODUCTS – NOT FDIC INSURED – NO BANK GUARANTEE – MAY LOSE VALUE

---

GILMORE & ASSOCIATES, INC.
ENGINEERING & CONSULTING SERVICES

PROUD TO SUPPORT

Baruch S. Blumberg Institute | Pennsylvania Biotechnology Center

gilmore-assoc.com 800.344.5667

---

Penn Color and Penn E&R
are proud to sponsor the

2020 Regional
Biotechnology Conference
and the efforts of the
Baruch S. Blumberg Institute.

www.penncolor.com
The Hepatitis B Foundation cordially invites you to the

30th Anniversary Gala

When • Friday, April 30, 2021 - 6PM
www.hepb.org
215-489-4900
West is By Your Side to Simplify the Journey™

Responsive to the unique needs of biologic, pharma, generic drug product, West helps to:

- Reduce development and supply risk
- Accelerate your path to market
- Minimize the total cost of ownership
- Improve the patient experience

Contact West today for more information at westpharma.com

Your one stop shop for all Essential Business Services

ACCOUNTING | FINANCE | TAXES | INSURANCE | HR+PAYROLL